Breaking News

Otolith Labs Closes $3.3 Million in Seed Funding and Receives FDA Breakthrough Device Designation

Investors include Mark Cuban and other experienced MedTech investors including 4 leading ENTs. Otolith Labs’ noninvasive Vestibular System Masking (nVSM) technology is designed to provide acute treatment for vestibulogenic vertigo. Otolith’s headworn medical device applies localized mechanical stimulation to the vestibular system through calibrated vibrations. It is primarily intended for use by chronic vertigo patients, for whom there are limited treatment options.

In The News

Selected as Top Five Finalist  for the MedTech Innovator Execution Award Competition

Selected as Top Five Finalist for the MedTech Innovator Execution Award Competition

The selection was made during the pre-conference virtual live stream on September 22, 2021.

MedTech Innovator Selects Otolith in Top 50 Medtech Startups

MedTech Innovator Selects Otolith in Top 50 Medtech Startups

MedTech innovator unveils top 50 medtech startups selected for Annual showcase and accelerator, which includes Otolith Labs.

D.C. Biotech is Raising Millions to Advance Medical Device for Vertigo

D.C. Biotech is Raising Millions to Advance Medical Device for Vertigo

CEO Sam Owen discusses Otolith Labs usage of investor funding and the companies journey the past few years.

Otolith Receives Breakthrough Device Designation from FDA

Otolith Receives Breakthrough Device Designation from FDA

Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.

Selected in 101 Best Washington Based Medical Device Startups

Selected in 101 Best Washington Based Medical Device Startups

Otolith Labs selected as one of 101 top Washington based Medical Device companies by The Startup Pill.

Inventor May Have Cured Motion Sickness Without Drugs, Could Mean a Lot to the US Military

Inventor May Have Cured Motion Sickness Without Drugs, Could Mean a Lot to the US Military

Discuses how Otolith technology could effect military training.

Otolith Presents at Auditory & Vestibular Translational Research Day

Otolith Presents at Auditory & Vestibular Translational Research Day

Otolith’s Chief Science Officier, Didier Depireux, Ph. D, presented on Otolith’s novel vertigo device.

Increased Bone Conducted Vibration Reduces Motion Sickness

Increased Bone Conducted Vibration Reduces Motion Sickness

Results from a study testing bone conductive vibrations proved the device decreases nausea from motion sickness.

Electronic Headband for Drug-Free Motion Sickness Therapy

Electronic Headband for Drug-Free Motion Sickness Therapy

Medgadget describes Otolith Labs technology and the positive impact it has on motion sickness symptoms.

NASA iTech 2020 Cycle 1 Winner

NASA iTech 2020 Cycle 1 Winner

Through NASA’s iTech initiative, the agency discovers and assesses technologies that could help it accomplish future missions. Otolith Labs was one of the three winning teams in 2020.

Development of Therapeutic Headband for Vertigo Sufferers

Development of Therapeutic Headband for Vertigo Sufferers

Washington Business Journal talks about Otolith Labs plan for FDA approval and the funding neccesary. 

This New Device Could Solve VR Motion Sickness

This New Device Could Solve VR Motion Sickness

OtoTech combats motion-induced nausea, including side effects of VR usage, without the side effects of drugs.

Recognition

Medtech Innovator Accelerator

Medtech Innovator Accelerator

Halcyon                    Incubator

Halcyon Incubator

NASA iTech 2020 Cycle 1 Winner

NASA iTech 2020 Cycle 1 Winner

© 2021 Otolith Labs, Inc.